← Back

Zentalis Pharmaceuticals Llc

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. Its lead candidate, azenosertib, is in a Phase 3 clinical trial for ovarian cancer and other tumor types. The company also conducted a Phase 1 study of azenosertib monotherapy in solid tumors (ZN-c3-001) and a Phase 1/2 trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer (MAMMOTH, ZN-c3-006). Zentalis has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. The company was incorporated in 2014 and is based in San Diego, California.

Country
Price · split & dividend adjusted
News & notes moving ZNTL
United States
ZNTL▼2

Zentalis Pharmaceuticals prices 23M share offering at $3.50

Zentalis Pharmaceuticals announced the pricing of an underwritten public offering of 23 million shares of its common stock at $3.50 per share. Gross proceeds are expected to be approximately $80.5 million before deducting underwriting discounts, commissions, and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 3.45 million shares at the same price. Net proceeds will fund clinical trials, preclinical studies, regulatory filings, manufacturing, and companion diagnostic development for its lead candidate, azenosertib, as well as pre-commercial activities, capital expenditures, and general corporate purposes. The offering is scheduled to close on August 17, 2026.
ZNTL ▼
ZNTL · Capital · Negative Pricing of a public offering dilutes existing shareholders.
Read original ↗
Seeking Alpha·51dRead more →
Biotech & Genomic Medicine▲

Zentalis to present overall survival data for azenosertib in ovarian cancer at ESMO 2026

Zentalis Pharmaceuticals announced it will present overall survival results from the DENALI Part 1b study of its investigational WEE1 inhibitor azenosertib at the European Society for Medical Oncology Congress 2026 in Madrid. The data, accepted as a rapid oral presentation, highlight long-term survival benefits in patients with Cyclin E1-positive platinum-resistant ovarian cancer. The company will also present a trial-in-progress poster on ASPENOVA, a Phase 3 study of azenosertib monotherapy versus standard-of-care chemotherapy in the same biomarker-selected population. DENALI Part 1b enrolled patients regardless of Cyclin E1 expression and treated them with azenosertib at 400 mg once daily on a 5-days-on, 2-days-off schedule. Zentalis is advancing azenosertib in registration-intended monotherapy trials for this high-unmet-need group, which represents approximately 50% of platinum-resistant ovarian cancer patients.
ZNTL ▲
Biotech & Genomic Medicine
About megatrends
Biotech & Genomic Medicine › Oncology Therapeutics Competition
ZNTL · Technology · Positive Positive overall survival data and trial progress for azenosertib in ovarian cancer.
Read original ↗
GlobeNewswire·79dRead more →
© 2026 MarketDXAsset